Ignite Creation Date:
2024-07-17 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06501625
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-07-09
Brief Title:
Ivosidenib Plus Durvalumab and GemcitabineCisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Sponsor:
Institut de Recherches Internationales Servier
Organization:
Servier
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-12-16
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-09-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-01-15
Completion Date Type:
ESTIMATED
First Submit Date:
2024-07-09
First Submit QC Date:
None
Study First Post Date:
2024-07-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-09
Last Update Post Date:
2024-07-15
Last Update Post Date Type:
ESTIMATED